Bispecific antibodies (commonly abbreviated as BsAbs) are an innovative class of biological drugs capable of simultaneously binding to two different antigens or epitopes.

This FDA approval of the ARCT-032 IND application allows the Company to commence a Phase 2 multiple ascending dose study to assess the safety, tolerability, and efficacy.

Sep 5th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Antabio has reported the successful completion of its Phase 1 clinical trial for MEM-ANT3310 conducted with healthy participants.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the National Medical Products Administration (NMPA) has approved their investigational new drug (IND) application for the clinical trial of HLX17

IgGenix revealed promising data about its primary candidate, IGNX001. This candidate is an IgG4 monoclonal antibody therapy designed to treat peanut allergy.

Finerenone significantly improved cardiovascular outcomes in adults with a prevalent form of heart failure, addressing a significant medical need.

Tolebrutinib achieves main goal in HERCULES phase 3 trial, proving to be the first to reduce disability progression in non-relapsing secondary progressive multiple sclerosis.

we will use the drug Fulzerasib as an example to demonstrate how to quickly obtain information about its chemical structure and patent situation using the Synapse database and Patsnap Chemical.

Grit Biotechnology gains U.S. FDA approval for GT201 investigational new drug application, a genetically modified TIL, after receiving Chinese IND approval.

On September 2, 2024, Arrowhead Pharmaceuticals (referred to as "Arrowhead") announced the results of the Phase 3 PALISADE study for plozasiran in patients with familial chylomicronemia syndrome (FCS).

FDA Grants Emergency Use Authorization to Novavax's Updated COVID-19 Vaccine for Ages 12 and Up.